Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
SEATTLE, Nov. 17, 2025 (GLOBE NEWSWIRE) — Pluristyx announced today the launch of a project up to $1.4 million, supported and funded by Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The project will create and distribute a genetically engineered induced pluripotent stem cell (iPSC) line, providing developers […]